Search Results 71-80 of 403 for ★베스트토토안전확인【평생베스트.com】베스트토토검증★

  1. https://www.mayoclinic.org/condition_consolidated_concepts.xml

  2. https://www.mayoclinic.org/organization_concepts.xml

  3. A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval - Mayo Clinic

    ... best. Study IDs. Site IRB. Rochester, Minnesota: 15-001739. NCT ID: NCT02419716. Sponsor Protocol Number: Exact Sciences 2014-01. About this study. The purpose ...

  4. Testicular Cancer Clinical Trials - Mayo Clinic Research

    This phase I trial studies the side effects and the best dose of dabrafenib in treating patients with solid tumors and kidney or liver dysfunction.

  5. Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Estrogen Receptor Positive (ER+) Breast Cancer - Mayo Clinic

    ... best. Study phase. 1. During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later ...

  6. Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or In Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer - Mayo Clinic

    ... best. Study phase. 2. During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later ...

  7. Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery - Mayo Clinic

    About this study. This phase I trial studies the side effects and the best dose of trametinib when given together with combination chemotherapy and ...

  8. Brachial plexus injury care at Mayo Clinic

    Surgeons, radiologists, physical therapists and other specialists collaborate as a team to evaluate your condition and choose the best treatment. At Mayo ...

  9. Active Clearance Technology (ACT) Registry - Mayo Clinic

    ... best. Study IDs. Site IRB. Rochester, Minnesota: 15-006388. NCT ID: NCT02682849. Sponsor Protocol Number: 15-006388. About this study. The purpose of this study ...

  10. Study of rSIFN-co for Patients with Advanced Solid Tumors - Mayo Clinic

    ... best. Study phase. 1. During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later ...